Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments

Nowadays diabetes, especially type 2 diabetes (which is strongly related to the Western diet and life-style), has developed worldwide into an epidemic disease. Nanomedicine aims to provide novel tools for diagnosis, therapy and point-of-care management of patients. Several nanotechnological approach...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Krol, Silke (VerfasserIn) , Ellis-Behnke, Rutledge (VerfasserIn) , Marchetti, Piero (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Maturitas
Year: 2011, Jahrgang: 73, Heft: 1, Pages: 61-67
ISSN:1873-4111
DOI:10.1016/j.maturitas.2011.12.004
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.maturitas.2011.12.004
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0378512211004142
Volltext
Verfasserangaben:Silke Krol, Rutledge Ellis-Behnke, Piero Marchetti

MARC

LEADER 00000caa a2200000 c 4500
001 1576845680
003 DE-627
005 20220814174301.0
007 cr uuu---uuuuu
008 180626r20122011xx |||||o 00| ||eng c
024 7 |a 10.1016/j.maturitas.2011.12.004  |2 doi 
035 |a (DE-627)1576845680 
035 |a (DE-576)506845680 
035 |a (DE-599)BSZ506845680 
035 |a (OCoLC)1341012638 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Krol, Silke  |d 1968-  |e VerfasserIn  |0 (DE-588)122564790  |0 (DE-627)705954013  |0 (DE-576)293325952  |4 aut 
245 1 0 |a Nanomedicine for treatment of diabetes in an aging population  |b state-of-the-art and future developments  |c Silke Krol, Rutledge Ellis-Behnke, Piero Marchetti 
264 1 |c 2012 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 28 December 2011 
500 |a Gesehen am 26.06.2018 
520 |a Nowadays diabetes, especially type 2 diabetes (which is strongly related to the Western diet and life-style), has developed worldwide into an epidemic disease. Nanomedicine aims to provide novel tools for diagnosis, therapy and point-of-care management of patients. Several nanotechnological approaches were developed to improve life quality for patients with insulin-dependent diabetes. They facilitate blood glucose management by non-invasive glucose measurement as well as insulin administration mainly by delivering the fragile protein as protected and targeted formulation via nasal or oral route. In the present review the oral or nasal insulin delivery by polymeric nanoparticles is discussed with focus on physiological change either related to the disease, diabetes or age-related metabolic variations influencing insulin release and bioavailability. One critical point is that new generations of targeted nanoparticle based drugs are developed and optimized for certain metabolic conditions. These conditions may change with age or disease. The influence of age-related factors such as immaturity in very young age, metabolic and physiologic changes in old age or insufficient animal models are still under-investigated not only in nanomedicine but also generally in pharmacology. Summarizing it can be noted that the bioavailability of insulin administered via routes others than subcutaneously is comparably low (max. 60%). Moreover factors like changed gut permeability as described for diabetes type 1 or other metabolic peculiarities such as insulin resistance in case of type 2 diabetes also play a role in affecting the development of novel nanoparticulated drug preparations and can be responsible for unsuccessful translation of promising animal results into human therapy. In future insulin nanoparticle development for diabetes must consider not only requirements imposed by the drug but also metabolic changes inflicted by disease or by age. Moreover new approaches are required for prevention of the disease. 
534 |c 2011 
650 4 |a Age-related changes 
650 4 |a Diabetes 
650 4 |a Mucosa-adhesive 
650 4 |a Nanoparticulated insulin 
650 4 |a Nasal 
650 4 |a Oral/intestinal 
700 1 |a Ellis-Behnke, Rutledge  |e VerfasserIn  |0 (DE-588)1156309182  |0 (DE-627)1018859950  |0 (DE-576)426349830  |4 aut 
700 1 |a Marchetti, Piero  |e VerfasserIn  |0 (DE-588)1161749632  |0 (DE-627)1025201604  |0 (DE-576)506845125  |4 aut 
773 0 8 |i Enthalten in  |t Maturitas  |d Amsterdam [u.a.] : Elsevier Science, 1978  |g 73(2012), 1, Seite 61-67  |h Online-Ressource  |w (DE-627)320467279  |w (DE-600)2008054-2  |w (DE-576)096290544  |x 1873-4111  |7 nnas  |a Nanomedicine for treatment of diabetes in an aging population state-of-the-art and future developments 
773 1 8 |g volume:73  |g year:2012  |g number:1  |g pages:61-67  |g extent:7  |a Nanomedicine for treatment of diabetes in an aging population state-of-the-art and future developments 
856 4 0 |u http://dx.doi.org/10.1016/j.maturitas.2011.12.004  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0378512211004142  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180626 
993 |a Article 
994 |a 2012 
998 |g 1156309182  |a Ellis-Behnke, Rutledge  |m 1156309182:Ellis-Behnke, Rutledge  |d 60000  |d 61700  |e 60000PE1156309182  |e 61700PE1156309182  |k 0/60000/  |k 1/60000/61700/  |p 2 
999 |a KXP-PPN1576845680  |e 3013739940 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Silke Krol, Rutledge Ellis-Behnke, Piero Marchetti"]},"id":{"doi":["10.1016/j.maturitas.2011.12.004"],"eki":["1576845680"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2008054-2"],"eki":["320467279"],"issn":["1873-4111"]},"origin":[{"dateIssuedDisp":"1978-","publisher":"Elsevier Science","dateIssuedKey":"1978","publisherPlace":"Amsterdam [u.a.]"}],"recId":"320467279","language":["eng"],"note":["Gesehen am 20.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Nanomedicine for treatment of diabetes in an aging population state-of-the-art and future developmentsMaturitas","part":{"issue":"1","pages":"61-67","year":"2012","extent":"7","text":"73(2012), 1, Seite 61-67","volume":"73"},"pubHistory":["1.1978/79 -"],"title":[{"title_sort":"Maturitas","title":"Maturitas","subtitle":"The European menopause journal"}]}],"physDesc":[{"extent":"7 S."}],"person":[{"role":"aut","display":"Krol, Silke","roleDisplay":"VerfasserIn","given":"Silke","family":"Krol"},{"display":"Ellis-Behnke, Rutledge","roleDisplay":"VerfasserIn","role":"aut","family":"Ellis-Behnke","given":"Rutledge"},{"family":"Marchetti","given":"Piero","roleDisplay":"VerfasserIn","display":"Marchetti, Piero","role":"aut"}],"title":[{"title":"Nanomedicine for treatment of diabetes in an aging population","subtitle":"state-of-the-art and future developments","title_sort":"Nanomedicine for treatment of diabetes in an aging population"}],"recId":"1576845680","language":["eng"],"note":["Available online 28 December 2011","Gesehen am 26.06.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a KROLSILKEENANOMEDICI2012